Tharimmune(THAR) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Tharimmune Inc - Board Expands to Nine Members - SEC Filing
ReutersApr 28 17:27 ET
Express News | Tharimmune Says FDA Confirmed No Additional Trials Appear To Be Necessary Prior To A 505(b)(2) New Drug Application Submission
BenzingaApr 28 08:14 ET
Tharimmune Strengthens Strategic Leadership With the Appointment of Vincent LoPriore to Its Board of Directors
AccesswireApr 15 09:00 ET
Tharimmune Reports Preclinical Data for Dual-Target Biologics
MT NewswiresApr 7 10:59 ET
Express News | Fw: [Ext] News: Tharimmune Announces Positive Data With Novel Biparatopic Pd-1/Vegf and Multispecific Her2/Her3 Biologics Leveraging Proprietary Epiclick(Tm) Technology
ReutersApr 7 08:15 ET
Tharimmune Announces Preclinical Data For HS1940
BenzingaApr 7 08:04 ET

Comments

Jaguar8

10 hours ago

🟢Watchlist, APRIL 30,2025, Wednesday. NFA-DrJag8

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If ...

17

11

Trytosaveabit

Apr 28 20:22

news

$Tharimmune (THAR.US)$ Tharimmune Says FDA Confirmed No Additional Trials Appear To Be Necessary Prior To A 505(b)(2) New Drug Application Submission
Benzinga· 4 mins ago

Jaguar8

Apr 28 20:03

NEWS

$Tharimmune (THAR.US)$
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Monday, 28th April at 8:01 am
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (NASDAQ: THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced positive feedback from the U.S. Food and Drug A...

3

Teddy123

Apr 7 22:32

Biotech R&D Analysis

$Tharimmune (THAR.US)$
Tharimmune's preclinical data announcement marks a meaningful advancement for their multispecific antibody platform. The company's EpiClick technology appears to be delivering on its promise of accessing novel epitopes with two key candidates now showing promising in vitro potency.
The PD-1/VEGF bispecific (HS1940) represents a rational combination of immuno-oncology and anti-angiogenesis approaches. With EC50 values of 2.1nM for PD-1 and 2.56nM for VEG...

Teddy123

Apr 7 22:32

Oncology investment analysis

$Tharimmune (THAR.US)$
This preclinical data release demonstrates Tharimmune's progress in leveraging their EpiClick platform to produce differentiated oncology assets. Both candidates target well-validated oncology pathways but with potentially novel approaches to epitope binding.
The PD-1/VEGF bispecific space has become increasingly competitive, with Summit Therapeutics' ivonescimab leading development in the US market. Tharimmune's HS1940 attempts differentiation ...

THAR Tharimmune

Trade Overview

Capital Trend

News

Comments

Market Insights

Latest News

Investment Course

Reassessing Chinese Assets

Discussing